|
Table No.
|
Table Title
|
|
Table 1.1-1
|
Patent information of aminopyralid in some countries/regions, as of July 2020
|
|
Table 1.1-2
|
Registration information of aminopyralid in Argentina, as of April 2019
|
|
Table 1.1-3
|
Registration information of aminopyralid in Australia, as of May 2020
|
|
Table 1.1-4
|
Registration information of aminopyralid in Belgium, as of April 2019
|
|
Table 1.1-5
|
Registration information of aminopyralid in Canada, as of May 2020
|
|
Table 1.1-6
|
Registration information of aminopyralid in China, as of May 2020
|
|
Table 1.1-7
|
Registration information of aminopyralid in Denmark, as of May 2020
|
|
Table 1.1-8
|
Registration information of aminopyralid in Finland, as of May 2020
|
|
Table 1.1-9
|
Registration information of aminopyralid in France, as of May 2020
|
|
Table 1.1-10
|
Registration information of aminopyralid in Greece, as of May 2020
|
|
Table 1.1-11
|
Registration information of aminopyralid in South Africa, as of April 2019
|
|
Table 1.1-12
|
Registration information of aminopyralid in Switzerland, as of May 2020
|
|
Table 1.1-13
|
Registration information of aminopyralid in the UK, as of June 2020
|
|
Table 1.1-14
|
Registration information of aminopyralid in Uruguay, as of May 2020
|
|
Table 1.1-15
|
Registration information of aminopyralid in the US, as of June 2020
|
|
Table 1.2-1
|
Patent information of flucetosulfuron in some countries/regions, as of July 2020
|
|
Table 1.2-2
|
Registration information of flucetosulfuron in China, as of May 2020
|
|
Table 1.3-1
|
Patent information of flufenpyr-ethyl in some countries/regions, as of July 2020
|
|
Table 1.4-1
|
Patent information of pyrasulfotole in some countries/regions, as of July 2020
|
|
Table 1.4-2
|
Registration information of pyrasulfotole in Australia, as of May 2020
|
|
Table 1.4-3
|
Registration information of pyrasulfotole in Canada, as of May 2020
|
|
Table 1.4-4
|
Registration information of pyrasulfotole in South Africa, as of April 2019
|
|
Table 1.4-5
|
Registration information of pyrasulfotole in the US, as of June 2020
|
|
Table 1.5-1
|
Patent information of pyroxasulfone in some countries/regions, as of July 2020
|
|
Table 1.5-2
|
Registration information of pyroxasulfone in Argentina, as of April 2019
|
|
Table 1.5-3
|
Registration information of pyroxasulfone in Australia, as of May 2020
|
|
Table 1.5-4
|
Registration information of pyroxasulfone in Canada, as of May 2020
|
|
Table 1.5-5
|
Registration information of pyroxasulfone in China, as of May 2020
|
|
Table 1.5-6
|
Registration information of pyroxasulfone in South Africa, as of April 2019
|
|
Table 1.6-1
|
Patent information of pyroxsulam in some countries/regions, as of July 2020
|
|
Table 1.6-2
|
Registration information of pyroxsulam in Australia, as of May 2020
|
|
Table 1.6-3
|
Registration information of pyroxsulam in Belgium, as of April 2019
|
|
Table 1.6-4
|
Registration information of pyroxsulam in Brazil, as of May 2020
|
|
Table 1.6-5
|
Registration information of pyroxsulam in Canada, as of May 2020
|
|
Table 1.6-6
|
Registration information of pyroxsulam in China, as of May 2020
|
|
Table 1.6-7
|
Registration information of pyroxsulam in Denmark, as of May 2020
|
|
Table 1.6-8
|
Registration information of pyroxsulam in Finland, as of May 2020
|
|
Table 1.6-9
|
Registration information of pyroxsulam in France, as of May 2020
|
|
Table 1.6-10
|
Registration information of pyroxsulam in Greece, as of June 2020
|
|
Table 1.6-11
|
Registration information of pyroxsulam in the Netherlands, as of May 2020
|
|
Table 1.6-12
|
Registration information of pyroxsulam in South Africa, as of April 2019
|
|
Table 1.6-13
|
Registration information of pyroxsulam in Switzerland, as of May 2020
|
|
Table 1.6-14
|
Registration information of pyroxsulam in the UK, as of June 2020
|
|
Table 1.6-15
|
Registration information of pyroxsulam in the US, as of June 2020
|
|
Table 1.7-1
|
Patent information of saflufenacil in some countries/regions, as of July 2020
|
|
Table 1.7-2
|
Registration information of saflufenacil in Argentina, as of April 2019
|
|
Table 1.7-3
|
Registration information of saflufenacil in Australia, as of May 2020
|
|
Table 1.7-4
|
Registration information of saflufenacil in Brazil, as of May 2020
|
|
Table 1.7-5
|
Registration information of saflufenacil in Canada, as of May 2020
|
|
Table 1.7-6
|
Registration information of saflufenacil in Chile, as of May 2020
|
|
Table 1.7-7
|
Registration information of saflufenacil in China, as of May 2020
|
|
Table 1.7-8
|
Registration information of saflufenacil in South Africa, as of April 2019
|
|
Table 1.7-9
|
Registration information of saflufenacil in Uruguay, as of May 2020
|
|
Table 1.8-1
|
Patent information of thiencarbazone-methyl in some countries/regions, as of July 2020
|
|
Table 1.8-2
|
Registration information of thiencarbazone-methyl in Argentina, as of April 2019
|
|
Table 1.8-3
|
Registration information of thiencarbazone-methyl in Belgium, as of April 2019
|
|
Table 1.8-4
|
Registration information of thiencarbazone-methyl in Canada, as of May 2020
|
|
Table 1.8-5
|
Registration information of thiencarbazone-methyl in China, as of May 2020
|
|
Table 1.8-6
|
Registration information of thiencarbazone-methyl in Denmark, as of May 2020
|
|
Table 1.8-7
|
Registration information of thiencarbazone-methyl in Finland, as of May 2020
|
|
Table 1.8-8
|
Registration information of thiencarbazone-methyl in France, as of June 2020
|
|
Table 1.8-9
|
Registration information of thiencarbazone-methyl in Greece, as of May 2020
|
|
Table 1.8-10
|
Registration information of thiencarbazone-methyl in the Netherlands, as of May 2020
|
|
Table 1.8-11
|
Registration information of thiencarbazone-methyl in Switzerland, as of May 2020
|
|
Table 1.8-12
|
Registration information of thiencarbazone-methyl in the UK, as of June 2020
|
|
Table 1.8-13
|
Registration information of thiencarbazone-methyl in Uruguay, as of May 2020
|
|
Table 1.8-14
|
Registration information of thiencarbazone-methyl in the US, as of June 2020
|
|
Table 1.9-1
|
Patent information of indaziflam in some countries/regions, as of July 2020
|
|
Table 1.9-2
|
Registration information of indaziflam in Argentina, as of April 2019
|
|
Table 1.9-3
|
Registration information of indaziflam in Australia, as of May 2020
|
|
Table 1.9-4
|
Registration information of indaziflam in Brazil, as of May 2020
|
|
Table 1.9-5
|
Registration information of indaziflam in Canada, as of May 2020
|
|
Table 1.9-6
|
Registration information of indaziflam in Chile, as of June 2020
|
|
Table 1.9-7
|
Registration information of indaziflam in South Africa, as of April 2019
|
|
Table 1.9-8
|
Registration information of indaziflam in Uruguay, as of May 2020
|
|
Table 1.9-9
|
Registration information of indaziflam in the US, as of June 2020
|
|
Table 2.1-1
|
Patent information of chlorantraniliprole in some countries/regions, as of July 2020
|
|
Table 2.1-2
|
Registration information of chlorantraniliprole in Australia, as of May 2020
|
|
Table 2.1-3
|
Registration information of chlorantraniliprole in Canada, as of May 2020
|
|
Table 2.1-4
|
Registration information of chlorantraniliprole in China, as of May 2020
|
|
Table 2.1-5
|
Registration information of chlorantraniliprole in France, as of May 2020
|
|
Table 2.1-6
|
Registration information of chlorantraniliprole in Greece, as of May 2020
|
|
Table 2.1-7
|
Registration information of chlorantraniliprole in the Netherlands, as of May 2020
|
|
Table 2.1-8
|
Registration information of chlorantraniliprole in South Africa, as of April 2019
|
|
Table 2.1-9
|
Registration information of chlorantraniliprole in Switzerland, as of May 2020
|
|
Table 2.1-10
|
Registration information of chlorantraniliprole in the UK, as of June 2020
|
|
Table 2.1-11
|
Registration information of chlorantraniliprole in the US, as of June 2020
|
|
Table 2.2-1
|
Patent information of pyrifluquinazon in some countries/regions, as of July 2020
|
|
Table 2.2-2
|
Registration information of pyrifluquinazon in the US, as of June 2020
|
|
Table 2.3-1
|
Patent information of cyantraniliprole in some countries/regions, as of July 2020
|
|
Table 2.3-2
|
Registration information of cyantraniliprole in Argentina, as of April 2019
|
|
Table 2.3-3
|
Registration information of cyantraniliprole in Australia, as of May 2020
|
|
Table 2.3-4
|
Registration information of cyantraniliprole in Belgium, as of April 2019
|
|
Table 2.3-5
|
Registration information of cyantraniliprole in Canada, as of May 2020
|
|
Table 2.3-6
|
Registration information of cyantraniliprole in China, as of May 2020
|
|
Table 2.3-7
|
Registration information of cyantraniliprole in Finland, as of May 2020
|
|
Table 2.3-8
|
Registration information of cyantraniliprole in France, as of May 2020
|
|
Table 2.3-9
|
Registration information of cyantraniliprole in Greece, as of July 2020
|
|
Table 2.3-10
|
Registration information of cyantraniliprole in the Netherlands, as of May 2020
|
|
Table 2.3-11
|
Registration information of cyantraniliprole in South Africa, as of April 2019
|
|
Table 2.3-12
|
Registration information of cyantraniliprole in the UK, as of June 2020
|
|
Table 2.3-13
|
Registration information of cyantraniliprole in the US, as of June 2020
|
|
Table 2.4-1
|
Patent informulation of cyflumetofen in some countries/regions, as of July 2020
|
|
Table 2.4-2
|
Registration information of cyflumetofen in Argentina, as of April 2019
|
|
Table 2.4-3
|
Registration information of cyflumetofen in Belgium, as of April 2019
|
|
Table 2.4-4
|
Registration information of cyflumetofen in Brazil, as of May 2020
|
|
Table 2.4-5
|
Registration information of cyflumetofen in Canada, as of May 2020
|
|
Table 2.4-6
|
Registration information of cyflumetofen in China, as of May 2020
|
|
Table 2.4-7
|
Registration information of cyflumetofen in France, as of May 2020
|
|
Table 2.4-8
|
Registration information of cyflumetofen in Greece, as of May 2020
|
|
Table 2.4-9
|
Registration information of cyflumetofen in the Netherlands, as of May 2020
|
|
Table 2.4-10
|
Registration information of cyflumetofen in the UK, as of June 2020
|
|
Table 2.4-11
|
Registration information of cyflumetofen in the US, as of June 2020
|
|
Table 2.5-1
|
Patent information of cyclaniliprole in some countries/regions, as of July 2020
|
|
Table 2.5-2
|
Registration information of cyclaniliprolen in Australia, as of May 2020
|
|
Table 2.5-3
|
Registration information of cyclaniliprole in Canada, as of June 2020
|
|
Table 2.5-4
|
Registration information of cyclaniliprole in the US, as of June 2020
|
|
Table 2.6-1
|
Patent information of spirotetramat in some countries/regions, as of June 2020
|
|
Table 2.6-2
|
Registration information of spirotetramat in Canada, as of June 2020
|
|
Table 2.6-3
|
Registration information of spirotetramat in China, as of June 2020
|
|
Table 2.6-4
|
Registration information of spirotetramat in Denmark, as of June 2020
|
|
Table 2.6-5
|
Registration information of spirotetramat in France, as of June 2020
|
|
Table 2.6-6
|
Registration information of spirotetramat in Greece, as of June 2020
|
|
Table 2.6-7
|
Registration information of spirotetramat in the Netherlands, as of June 2020
|
|
Table 2.6-8
|
Registration information of spirotetramat in the UK, as of June 2020
|
|
Table 2.6-9
|
Registration information of spirotetramat in Uruguay, as of June 2020
|
|
Table 2.6-10
|
Registration information of spirotetramat in the US, as of June 2020
|
|
Table 3.1-1
|
Patent information of fenpyrazamine in some countries/regions, as of July 2020
|
|
Table 3.1-2
|
Registration information of fenpyrazamine in Australia, as of July 2020
|
|
Table 3.1-3
|
Registration information of fenpyrazamine in Belgium, as of June 2020
|
|
Table 3.1-4
|
Registration information of fenpyrazamine in Chile, as of June 2020
|
|
Table 3.1-5
|
Registration information of fenpyrazamine in Denmark, as of June 2020
|
|
Table 3.1-6
|
Registration information of fenpyrazamine in Finland, as of May 2020
|
|
Table 3.1-7
|
Registration information of fenpyrazamine in France, as of May 2020
|
|
Table 3.1-8
|
Registration information of fenpyrazamine in Greece, as of May 2020
|
|
Table 3.1-9
|
Registration information of fenpyrazamine in the Netherlands, as of May 2020
|
|
Table 3.1-10
|
Registration information of fenpyrazamine in Switzerland, as of May 2020
|
|
Table 3.1-11
|
Registration information of fenpyrazamine in the UK, as of June 2020
|
|
Table 3.2-1
|
Patent information of mandipropamid in some countries/regions, as of July 2020
|
|
Table 3.2-2
|
Registration information of mandipropamid in Argentina, as of April 2019
|
|
Table 3.2-3
|
Registration information of mandipropamid in Australia, as of May 2020
|
|
Table 3.2-4
|
Registration information of mandipropamid in Belgium, as of April 2019
|
|
Table 3.2-5
|
Registration information of mandipropamid in Brazil, as of May 2020
|
|
Table 3.2-6
|
Registration information of mandipropamid in Canada, as of May 2020
|
|
Table 3.2-7
|
Registration information of mandipropamid in Chile, as of May 2020
|
|
Table 3.2-8
|
Registration information of mandipropamid in China, as of May 2020
|
|
Table 3.2-9
|
Registration information of mandipropamid in Denmark, as of May 2020
|
|
Table 3.2-10
|
Registration information of mandipropamid in Finland, as of May 2020
|
|
Table 3.2-11
|
Registration information of mandipropamid in France, as of May 2020
|
|
Table 3.2-12
|
Registration information of mandipropamid in Greece, as of May 2020
|
|
Table 3.2-13
|
Registration information of mandipropamid in the Netherlands, as of May 2020
|
|
Table 3.2-14
|
Registration information of mandipropamid in South Africa, as of April 2019
|
|
Table 3.2-15
|
Registration information of mandipropamid in Switzerland, as of May 2020
|
|
Table 3.2-16
|
Registration information of mandipropamid in the UK, as of June 2020
|
|
Table 3.2-17
|
Registration information of mandipropamid in the US, as of June 2020
|
|
Table 3.3-1
|
Patent information of penflufen in some countries/regions, as of July 2020
|
|
Table 3.3-2
|
Registration information of penflufen in Australia, as of May 2020
|
|
Table 3.3-3
|
Registration information of penflufen in Belgium, as of April 2019
|
|
Table 3.3-4
|
Registration information of penflufen in Canada, as of July 2020
|
|
Table 3.3-5
|
Registration information of penflufen in Chile, as of May 2020
|
|
Table 3.3-6
|
Registration information of penflufen in China, as of May 2020
|
|
Table 3.3-7
|
Registration information of penflufen in Denmark, as of May 2020
|
|
Table 3.3-8
|
Registration information of penflufen in Finland, as of May 2020
|
|
Table 3.3-9
|
Registration information of penflufen in the Netherlands, as of May 2020
|
|
Table 3.3-10
|
Registration information of penflufen in the UK, as of June 2020
|
|
Table 3.3-11
|
Registration information of penflufen in the US, as of June 2020
|
|
Table 3.4-1
|
Patent information of bixafen in some countries/regions, as of July 2020
|
|
Table 3.4-2
|
Registration information of bixafen in Argentina, as of April 2019
|
|
Table 3.4-3
|
Registration information of bixafen in Australia, as of May 2020
|
|
Table 3.4-4
|
Registration information of bixafen in Belgium, as of April 2019
|
|
Table 3.4-5
|
Registration information of bixafen in Chile, as of June 2020
|
|
Table 3.4-6
|
Registration information of bixafen in Denmark, as of May 2020
|
|
Table 3.4-7
|
Registration information of bixafen in Finland, as of May 2020
|
|
Table 3.4-8
|
Registration information of bixafen in France, as of May 2020
|
|
Table 3.4-9
|
Registration information of bixafen in the Netherlands, as of May 2020
|
|
Table 3.4-10
|
Registration information of bixafen in South Africa, as of April 2019
|
|
Table 3.4-11
|
Registration information of bixafen in Switzerland, as of July 2020
|
|
Table 3.4-12
|
Registration information of bixafen in the UK, as of June 2020
|
|
Table 3.4-13
|
Registration information of bixafen in Uruguay, as of May 2020
|
|
Table 3.4-14
|
Registration information of bixafen in the US, as of June 2020
|
|
Table 3.5-1
|
Patent information of fluopyram in some countries/regions, as of July 2020
|
|
Table 3.5-2
|
Registration information of fluopyram in Australia, as of May 2020
|
|
Table 3.5-3
|
Registration information of fluopyram in Belgium, as of April 2019
|
|
Table 3.5-4
|
Registration information of fluopyram in Brazil, as of May 2020
|
|
Table 3.5-5
|
Registration information of fluopyram in Canada, as of July 2020
|
|
Table 3.5-6
|
Registration information of fluopyram in China, as of May 2020
|
|
Table 3.5-7
|
Registration information of fluopyram in Denmark, as of May 2020
|
|
Table 3.5-8
|
Registration information of fluopyram in Finland, as of May 2020
|
|
Table 3.5-9
|
Registration information of fluopyram in France, as of May 2020
|
|
Table 3.5-10
|
Registration information of fluopyram in Greece, as of May 2020
|
|
Table 3.5-11
|
Registration information of fluopyram in the Netherlands, as of May 2020
|
|
Table 3.5-12
|
Registration information of fluopyram in South Africa, as of April 2019
|
|
Table 3.5-13
|
Registration information of fluopyram in Switzerland, as of May 2020
|
|
Table 3.5-14
|
Registration information of fluopyram in the UK, as of June 2020
|
|
Table 3.5-15
|
Registration information of fluopyram in the US, as of June 2020
|
|
Table 3.6-1
|
Patent information of isopyrazam in some countries/regions, as of July 2020
|
|
Table 3.6-2
|
Registration information of isopyrazam in Argentina, as of April 2019
|
|
Table 3.6-3
|
Registration information of isopyrazam in Australia, as of May 2020
|
|
Table 3.6-4
|
Registration information of isopyrazam in Belgium, as of April 2019
|
|
Table 3.6-5
|
Registration information of isopyrazam in China, as of May 2020
|
|
Table 3.6-6
|
Registration information of isopyrazam in France, as of May 2020
|
|
Table 3.6-7
|
Registration information of isopyrazam in Greece, as of May 2020
|
|
Table 3.6-8
|
Registration information of isopyrazam in the Netherlands, as of May 2020
|
|
Table 3.6-9
|
Registration information of isopyrazam in the UK, as of June 2020
|
|
Table 3.6-10
|
Registration information of isopyrazam in Uruguay, as of May 2020
|
|
Table 3.7-1
|
Patent information of sedaxane in some countries/regions, as of July 2020
|
|
Table 3.7-2
|
Registration information of sedaxane in Argentina, as of April 2019
|
|
Table 3.7-3
|
Registration information of sedaxane in Australia, as of May 2020
|
|
Table 3.7-4
|
Registration information of sedaxane in Canada, as of May 2020
|
|
Table 3.7-5
|
Registration information of sedaxane in Chile, as of April 2019
|
|
Table 3.7-6
|
Registration information of sedaxane in China, as of May 2020
|
|
Table 3.7-7
|
Registration information of sedaxane in Denmark, as of May 2020
|
|
Table 3.7-8
|
Registration information of sedaxane in Finland, as of May 2020
|
|
Table 3.7-9
|
Registration information of sedaxane in France, as of May 2020
|
|
Table 3.7-10
|
Registration information of sedaxane in Greece, as of May 2020
|
|
Table 3.7-11
|
Registration information of sedaxane in the UK, as of June 2020
|
|
Table 3.7-12
|
Registration information of sedaxane in Uruguay, as of May 2020
|
|
Table 3.7-13
|
Registration information of sedaxane in the US, as of June 2020
|
|
Table 4.1-1
|
Patent information of cyprosulfamide in some countries/regions, as of July 2020
|
|
Table 4.1-2
|
Registration information of cyprosulfamide in Argentina, as of April 2019
|
|
Table 4.1-3
|
Registration information of cyprosulfamide in Belgium, as of April 2019
|
|
Table 4.1-4
|
Registration information of cyprosulfamide in Canada, as of May 2020
|
|
Table 4.1-5
|
Registration information of cyprosulfamide in France, as of May 2020
|
|
Table 4.1-6
|
Registration information of cyprosulfamide in Greece, as of May 2020
|
|
Table 4.1-7
|
Registration information of cyprosulfamide in the Netherlands, as of May 2020
|